European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 26 February 2026 - 16:00

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 26 February 2026 - 15:35

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 26 February 2026 - 15:32

Human medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Yeytuo, lenacapavir, Date of authorisation: 25/08/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 26 February 2026 - 15:12

Human medicines European public assessment report (EPAR): Yeytuo, lenacapavir, Date of authorisation: 25/08/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Adenuric, febuxostat, Date of authorisation: 21/04/2008, Revision: 25, Status: Authorised

Submitted by Anonymous (not verified) on 26 February 2026 - 14:38

Human medicines European public assessment report (EPAR): Adenuric, febuxostat, Date of authorisation: 21/04/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 45, Status: Authorised

Submitted by Anonymous (not verified) on 26 February 2026 - 14:15

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 45, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness